Gilead Sciences, Inc. Declares Quarterly Dividend of $0.77 (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Wednesday, November 6th,Zacks Dividends reports. Investors of record on Friday, December 13th will be paid a dividend of 0.77 per share by the biopharmaceutical company on Monday, December 30th. This represents a $3.08 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Friday, December 13th.

Gilead Sciences has raised its dividend by an average of 3.3% annually over the last three years. Gilead Sciences has a dividend payout ratio of 42.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Gilead Sciences to earn $7.28 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 42.3%.

Gilead Sciences Stock Down 1.1 %

Shares of NASDAQ GILD traded down $1.06 during midday trading on Friday, hitting $96.84. The company’s stock had a trading volume of 703,607 shares, compared to its average volume of 7,017,759. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market capitalization of $120.56 billion, a price-to-earnings ratio of 118.29, a price-to-earnings-growth ratio of 3.13 and a beta of 0.17. The business’s fifty day simple moving average is $84.58 and its two-hundred day simple moving average is $74.67. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $98.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the company earned $2.29 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences will post 3.75 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GILD. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Cantor Fitzgerald lifted their price target on shares of Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Thursday. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Oppenheimer lifted their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday. Twelve investment analysts have rated the stock with a hold rating, ten have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $90.71.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 62,437 shares of company stock valued at $5,374,825. Corporate insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.